2020 Fiscal Year Final Research Report
The pathologic clarification of Plexin D1-IgG-related neuropathic pain
| Project/Area Number |
19K17037
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 52020:Neurology-related
|
|---|
| Research Institution | Kyushu University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2019-04-01 – 2021-03-31
|
| Keywords | 神経障害性疼痛 / 抗Plexin D1抗体 / 自己抗体 / 小径線維ニューロパチー |
|---|
| Outline of Final Research Achievements |
In this study, we determined whether anti-Plexin D1 antibody (Plexin D1-IgG), which is associated with neuropathic pain (NP) and binds to pain-conducting small unmyelinated dorsal root ganglion neurons, exists in patients with idiopathic painful trigeminal neuropathy (IPTN) and small fiber neuropathy (SFN). Serum Plexin D1-IgG was detected in 14.3% of IPTN patients and 12.7% of SFN patients. Plexin D1-IgG derived from NP patients could induce a mechanical pain hypersensitivity by passive transfer to mice 24 h after intrathecal injection. Plexin D1-IgG is pathogenic but with low prevalence in IPTN and SFN.
|
| Free Research Field |
神経障害性疼痛
|
| Academic Significance and Societal Importance of the Research Achievements |
本研究により、抗Plexin D1抗体が生体内において神経障害性疼痛の発症における病原性を有することが明らかとなり、また、これまで原因不明とされてきた神経障害性疼痛疾患の一部において存在することが示されたことから、抗Plexin D1抗体は神経障害性疼痛の診断バイオマーカーの候補と考えられた。今後は、抗Plexin D1抗体を標的とする免疫治療により鎮痛効果が得られるか検証していく必要があると考えられた。
|
